Cryo-EM structure enabling virtual screening for the discovery of highly potent TRPM3 antagonists with analgesic efficacy.

Summary

Using cryo-EM structures of human TRPM3, the authors identified a compact binding pocket that enabled virtual screening and lead optimization to a picomolar antagonist with favorable drug-like properties. The compound produced strong, dose-dependent analgesia in rodent neuropathic and migraine pain models, validating TRPM3 as a non-opioid analgesic target.

Key Findings

• Cryo-EM resolved human TRPM3 structures and revealed a compact ligand-binding pocket.
• Virtual screening and structure-based optimization produced a picomolar TRPM3 antagonist with drug-like properties.
• The lead compound showed potent, dose-dependent analgesia across rodent neuropathic and migraine pain models.
• The work validates TRPM3 as a therapeutic target and outlines a structure-based pipeline for TRP channel drug discovery.

Clinical Implications

While preclinical, TRPM3 antagonism could yield non-opioid perioperative and chronic pain options with reduced respiratory depression and dependence risk. Translation will require first-in-human safety, selectivity, and efficacy trials.

Limitations

• Preclinical evidence only; no human pharmacokinetic or safety data
• Selectivity, off-target effects within the TRP family, and long-term toxicity remain to be established

Future Directions

Advance to IND-enabling studies including selectivity profiling, GLP toxicology, pharmacokinetics, and early-phase clinical trials to assess safety and analgesic efficacy.